Bicara Therapeutics Inc. BCAX 深 滬
等待開盤 04-02 09:30:00 美东时间
20.50
+0.610
+3.07%
華盛通- 最 高21.05
- 今 開19.98
- 成交量 67.90万股
- 最 低 19.78
- 昨 收 19.89
- 總市值 13.42亿
- 52周最高 21.05
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.80
- 委 比 -90.81%
- 總股本 6546.72万
- 歷史最高 28.09
- 量 比 1.02
- 振 幅 6.39%
- 歷史最低 7.80
- 每 手 1
- 風險率 3.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Axe Compute (NASDAQ:AGPU) shares increased by 23.0% to $4.38 during We...
今天 05:05
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target
Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.
03-31 22:14
Bicara publishes corporate presentation on ficerafusp alfa in HPV-negative head and neck cancer
Bicara publishes corporate presentation on ficerafusp alfa in HPV-negative head and neck cancer Bicara outlined development strategy for lead asset ficerafusp alfa (FICERA), an EGFR-directed antibody bound to a TGF-β ligand trap, targeting first-line recurrent or metastatic HPV-negative head and nec
03-30 20:31
Bicara FY25 net loss widens to $138 million; Q4 net loss rises 78% to $37 million
Bicara FY25 net loss widens to $138 million; Q4 net loss rises 78% to $37 million Bicara posted a Q4 net loss of USD 37 million, more than doubled from a year earlier. Full-year net loss widened to USD 140 million, while R&D spending climbed to USD 130 million due to costs tied to the FORTIFI-HN01 p
03-30 19:34
Bicara Therapeutics Q4 EPS $(0.68), Inline
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the same period last year.
03-30 19:33
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
Bicara Therapeutics announced it will report Q4 and full year 2025 financial results and business updates on March 30, 2026, followed by a conference call. Registration details and a webcast link are available on its website. The company focuses on developing bifunctional therapies for solid tumors, with its lead program targeting EGFR and TGF-β pathways.
03-23 12:30
Bicara Therapeutics Grants New Hire Stock Option for 115,000 Shares Under 2026 Inducement Plan
Bicara Therapeutics Grants New Hire Stock Option for 115,000 Shares Under 2026 Inducement Plan Bicara Therapeutics Inc. granted a new employee a non-qualified stock option to buy 115,000 shares at an exercise price of $17.59 per share, matching the March 2, 2026 Nasdaq closing price. The award was m
03-04 21:30
